Abstract
The protamine zinc insulin now generally employed has proved valuable in the treatment of diabetes, but it has become increasingly evident that for many diabetic patients it is not ideal for maintenance therapy. This paper is the report of clinical investigations with a new form of modified protamine zinc insulin which has revealed distinct advantages in a series of 62 patients. The use of the slow acting standard protamine zinc insulin has permitted a reduction in the number of injections necessary in the great majority of cases of diabetes. It has also diminished the wide fluctuations in the blood sugar occurring with several daily injections of regular insulin. It was hoped that good maintenance therapy in nearly all cases of diabetes could be established with a single daily injection of protamine zinc insulin. This hope has not been realized. In the six years since its introduction in February 1937 much
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
